Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

March 31, 2026

Conditions

Relapsed/Refractory Classical Hodgkin Lymphoma

Interventions

DRUG

Brentuximab vedotin

3 cycles of Brentuximab vedotin and DHAP

Trial Locations (1)

RECRUITING

Hyeon-Seok Eom, Goyang-si

All Listed Sponsors

lead

National Cancer Center, Korea

OTHER_GOV